Bryn Pharma Expands Corporate Leadership with Three New Executive Hires and Additional Board Appointment

Nasal Epinephrine Delivery Innovator Advances Commercialization Readiness Ahead of FDA Review of Investigational Intranasal Delivery System

RALEIGH, N.C.–(BUSINESS WIRE)–#anaphylaxis—Bryn Pharma, LLC, a privately held pharmaceutical company dedicated to finding a better way for patients and caregivers to treat anaphylaxis, announced today the addition of three new executives to its leadership team: Nurry Hong, Chief Strategy and Business Development Officer; Steve Killmeyer, Chief Financial Officer (CFO); and, Lisa Lucifero, VP, Head of Human Resources. Michael Kaseta, CFO of Liquidia Corporation (Nasdaq: LQKA), has also been appointed to Bryn’s Board of Directors. All positions are effective immediately. The addition of these key leadership team members comes at a critical time as Bryn prepares for the U.S. Food and Drug Administration approval and market launch of its innovative intranasal spray UTULY™, an investigational self-administered form of epinephrine being studied for the treatment of type 1 allergic reactions, including anaphylaxis.

“Nurry, Steve and Lisa are trusted industry veterans with decades of experience in the pharma industry and food allergy space. They each bring essential experience and skill sets to Bryn as we continue to advance toward market entry of UTULY. Mike’s extensive pharmaceutical financial expertise is a significant addition to our Board,” said Sandy Loreaux, CEO. “The food allergy community is anxiously awaiting an innovative, needle-free epinephrine alternative that also offers rapid uptake. We are thrilled to welcome this dynamic and experienced group of leaders who will usher in a truly better way of treating anaphylaxis.”

Nurry Hong serves as Chief Strategy and Business Development Officer for Bryn, where he works closely with other members of Bryn’s leadership team and the Board of Directors to create a clear organizational vision and ensure execution of key strategic, business growth and capital initiatives. He is an accomplished senior life sciences executive and biotech entrepreneur with over 20 years of experience spanning multiple senior management and advisory roles. He has worked on behalf of global public biopharma, private biotech, seed-stage ventures, venture capital and non-profit research organizations. He is a recognized leader in food allergy and brings expertise in strategy, biotech start-up creation and growth, finance, business development, patient-driven product development and commercialization, health economics and market access, and operations. Most recently, Nurry served as CEO of Pareto Bio, a seed-stage biopharma company advancing innovative microbiome discoveries with the goal of treating and preventing atopic diseases including food allergy. He previously served as Chief of Strategy and Innovation for Food Allergy Research & Education (FARE), the largest food allergy non-profit organization in the United States. As a father of a son with multiple food allergies, Nurry is a passionate patient advocate who has focused his professional efforts to advance innovations to solve the needs of patients suffering from severe allergies. Nurry earned his BA in Business Finance and Information Systems from the University of Washington.

Steve Killmeyer serves as Bryn’s CFO and is responsible for all financial direction and oversight. He has over 15 years of finance experience in the pharmaceutical, biotech, and medical device industries. In his most recent role, he was the Head of Finance and Strategy for Aimmune Therapeutics, the startup pharmaceutical venture of Nestle Health Science. Steve joined Aimmune after over five years in the Life Science M&A practice at Deloitte Consulting where he worked with Pfizer, Johnson & Johnson, Becton Dickinson, ICU Medical, and other companies on M&A growth strategy and integration. Prior to management consulting, Steve worked as a healthcare private equity investor at HealthCor Partners and healthcare investment banker at Merrill Lynch. Steve earned his MBA from the Wharton School at the University of Pennsylvania, and his BS in Finance from Carnegie Mellon University.

Lisa Lucifero serves as Bryn’s VP and Head of Human Resources, where she oversees all Human Resources functions across the company. She plays an important role in building a solid HR strategy to attract and develop key talent as Bryn continues to expand the organization in preparation for the launch of UTULY. Lisa has extensive experience as a global HR leader in the pharmaceutical industry. She has a heavy concentration in organizational design and development, change leadership and communication, and talent acquisition. She has a proven track record in building programs and practices that support company culture and drive business outcomes in growth organizations. Prior to joining Bryn, Lisa held leadership roles across the biopharma and drug delivery space including DBV Technologies, Mallinckrodt Pharmaceuticals, Catalent Pharma Solutions, and Sanofi. She earned her BA in English and Government from Lehigh University and has been a certified Senior Human Resources Professional (SPHR) since 2008.

Bryn board member Michael Kaseta is currently the CFO of Liquidia Corporation, a position he has held since 2020. Previously, he served as CFO of Aerami Therapeutics, Inc., a privately held biotech focused on the development of improved therapies for the treatment of severe respiratory diseases, including pulmonary arterial hypertension. He spent several years at specialty pharmaceutical company Aralez Pharmaceuticals in roles of increasing responsibility, including Corporate Controller, Head of Finance and CFO. Prior to joining Aralez, Michael held various positions at global biopharmaceutical company Sanofi S.A., including Director of Technical Accounting, Vice President, Financial Shared Services, Vice President Sanofi NA Pharma Controlling, and CFO Sanofi North America, Global Services. Michael also serves on the Board of Directors of Alimera Sciences, Inc. He earned a BBA in accounting from James Madison University and is a licensed CPA (inactive) in the state of New Jersey.

About Bryn Pharma

Bryn Pharma, established in 2017, is a privately held pharmaceutical company founded by patients for patients. Bryn is focused on positively disrupting the existing market for epinephrine autoinjectors by delivering an accessible, easy-to-use alternative that better meets the needs of patients. Bryn Pharma seeks to provide this growing population at risk for anaphylaxis with A Better Way to be prepared for a life-threatening allergic reaction. For more information visit www.brynpharma.com.

Contacts

Rebecca Novak Tibbitt

[email protected]